MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular diseases, today announced that it will host a conference call and audio webcast on Thursday, August 8, 2019 at 1:30 PM Pacific Time to report its second quarter 2019 financial results and provide corporate updates.

Individuals can participate in the conference call by dialing 1-866-420-8347 (domestic) or 1-409-217-8241 (international), and refer to the “Adverum Biotechnologies Second Quarter 2019 Earnings Call.” The webcast will be accessible under Events and Presentations in the Investors section of the Company's website. The archived audio webcast will be available on the Adverum website following the call, and will be available for 30 days.

About Adverum Biotechnologies, Inc.

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has collaboration agreements with Regeneron Pharmaceuticals and Editas Medicine. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.

Investor and Media Inquiries:

Investors:
Amy Figueroa, CFA
Investor Relations Consultant
afigueroa@adverum.com
650-823-2704

Lee M. Stern, CFA
Solebury Trout
lstern@troutgroup.com
646-378-2922

Media:
Joshua R. Mansbach
Solebury Trout
jmansbach@troutgroup.com
646-378-2964

Source: Adverum Biotechnologies, Inc.